Figure 4: Parasite growth and griseofulvin pharmacokinetics in P. falciparum-infected subjects with griseofulvin. | Scientific Reports

Figure 4: Parasite growth and griseofulvin pharmacokinetics in P. falciparum-infected subjects with griseofulvin.

From: Griseofulvin impairs intraerythrocytic growth of Plasmodium falciparum through ferrochelatase inhibition but lacks activity in an experimental human infection study

Figure 4

Two cohorts were experimentally infected with blood stage P. falciparum and monitored for parasitemia by PCR. Day 0 corresponds with inoculation day for both cohorts. In Cohort 1 (a), four subjects (I1, I2, I3 and I5) began taking griseofulvin (500 mg BD) on Day 6 after inoculation (vertical line). Griseofulvin dosing ended on different days (Table 1) depending on PCR parasitaemia quantification. Dashed lines indicate the time-point when participants received treatment with artemether-lumefantrine (A/L). Subject I4 was a control subject and received treatment with mefloquine on Day 8. In Cohort 2 (b), two subjects took griseofulvin (500 mg BD) from Day -4 (4 days before infection) until Day 6. Both subjects in Cohort 2 were treated with artemether-lumefantrine on Day 7. Commencement of treatment with artemether-lumefantrine (A/L) is indicated with dashed lines. An additional eight subjects that did not receive griseofulvin (control group) were infected at the same time with the same inoculum; mean parasite levels (SD) for this group are shown as a comparison. (c) Concentrations of griseofulvin in plasma and red blood cells of the same Cohort 1 and Cohort 2 P. falciparum-infected subjects. Dashed lines indicate the time-point when dosing with griseofulvin ceased and participants received treatment with artemether-lumefantrine. Day 0 corresponds with inoculation day. Data represent the mean of duplicate assays.

Back to article page